HBPCF (Helix BioPharma) Shiller PE Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBPCF Helix BioPharma Corp HBPCF
24 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Helix BioPharma  (OTCPK:HBPCF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Helix BioPharma Shiller PE Ratio Related Terms


Helix BioPharma Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Shiller PE Ratio Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HBPCF vs VRTX, REGN, RVMD: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Helix BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Shiller PE Ratio falls into.


HBPCF
24GF Score
Helix BioPharma Corp HBPCF
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Helix BioPharma's E10 for the quarter that ended in Apr. 2026 is calculated as:

For example, Helix BioPharma's adjusted earnings per share data for the three months ended in Apr. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=-0.007/132.7364*132.7364
=-0.007

Current CPI (Apr. 2026) = 132.7364.

Helix BioPharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201607 -0.115 101.844 -0.150
201610 -0.151 102.002 -0.196
201701 -0.114 102.318 -0.148
201704 -0.112 103.029 -0.144
201707 -0.039 103.029 -0.050
201710 -0.079 103.424 -0.101
201801 -0.121 104.056 -0.154
201804 -0.079 105.320 -0.100
201807 -0.076 106.110 -0.095
201810 -0.038 105.952 -0.048
201901 -0.075 105.557 -0.094
201904 -0.075 107.453 -0.093
201907 -0.076 108.243 -0.093
201910 -0.076 107.927 -0.093
202001 -0.076 108.085 -0.093
202004 -0.071 107.216 -0.088
202007 -0.074 108.401 -0.091
202010 -0.151 108.638 -0.184
202101 -0.079 109.192 -0.096
202104 -0.080 110.851 -0.096
202107 -0.080 112.431 -0.094
202110 -0.040 113.695 -0.047
202201 -0.040 114.801 -0.046
202204 -0.040 118.357 -0.045
202207 0.000 120.964 0.000
202210 -0.037 121.517 -0.040
202301 -0.037 121.596 -0.040
202304 -0.037 123.571 -0.040
202307 -0.083 124.914 -0.088
202310 -0.022 125.310 -0.023
202401 -0.015 125.072 -0.016
202404 -0.029 126.890 -0.030
202407 -0.080 128.075 -0.083
202410 -0.022 127.838 -0.023
202501 -0.021 127.443 -0.022
202504 -0.021 129.102 -0.022
202507 -0.007 130.290 -0.007
202510 -0.007 130.603 -0.007
202601 -0.007 130.366 -0.007
202604 -0.007 132.736 -0.007

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
24GF Score

Get the complete analysis for HBPCF

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price